Theriva Biologics, Inc.

Contributing Author

Recent Articles by Theriva Biologics, Inc.

May-08	Theriva Biologics Announces Closing of $7.5 Million Public Offering TOVX GlobeNewswire
May-07	Theriva Biologics Announces Pricing of $7.5 Million Public Offering TOVX GlobeNewswire
May-07	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients TOVX GlobeNewswire